ImmunityBio Inc
IBRX
Get informed when a big investor buys or sells
+ Follow
Current Fair Value
181.1% downsideOvervalued by 181.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $7.51 Billion |
|---|---|
| Enterprise Value | $7.35 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.38 |
| Beta | 0.08 |
| Outstanding Shares | 1,026,874,000 |
Return
| Return on Equity | 98.32% |
|---|---|
| Return on Assets | -132.15% |
| Return on Invested Capital | -35.92% |
Valuation & Multiples
| P/E Ratio | -8.4 |
|---|---|
| PEG | -2.16 |
| Price to Sales | - |
| Price to Book Ratio | -6.95 |
| Enterprise Value to Revenue | 52.1 |
| Enterprise Value to EBIT | -35.34 |
| Enterprise Value to Net Income | -9 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | -0.05 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Next Earnings Call
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 4.7268▲ 392.44% |
|---|---|
| Total Calls | 18,300▼ 99.87% |
| Total Puts | 86,500▼ 99.23% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.79%▼ 16.60% |
|---|---|
| Total Invested | $82.58M▼ 93.93% |
| Investors Holding | 137▼ 281.00% |
ESG Score
No data
About ImmunityBio Inc
171 employees
CEO: Patrick Soon-Shiong NantKwest (NASDAQ: NK) is an innovative, clinical-stage, immunotherapy company focused on harnessing the power of the innate immune system to treat cancer and infectious diseases. NantKwest is the leading producer of clinical dose forms ...
Relevant Senate Committees
This committee provides critical analysis and revenue estimates for all tax legislation. Its work directly influences corporate tax structures and capital investment credits, which are fundamental to ImmunityBio's financial planning and profitability.
This committee controls taxation, trade, and entitlement spending. It directly impacts ImmunityBio's profitability through tax policy and market access/revenue through Medicare and Medicaid pricing and coverage decisions for its future therapies.
This committee directly regulates the FDA (critical for drug approval) and the NIH (major research funder). Its decisions profoundly impact ImmunityBio's ability to develop, test, and market its therapies, as well as the overall research landscape.